



MEDIA RELEASE

SAHPRA Warns the Public – Ms Pam Mohlabe does not work at SAHPRA

Embargo: Immediate Release

Pretoria, 2 September 2023 – The South African Health Products Regulatory Authority (SAHPRA) has been made aware that an ex-employee of SAHPRA is erroneously promoting the fact that she is still a SAHPRA employee.

Ms Pam Mohlabe is conducting interviews and also blatantly issuing cannabis licences for the purposes of medicinal cannabis processing.

Ms Mohlabe was in fact dismissed from SAHPRA in 2021 for fraud for the very same transgressions. She is purporting to represent SAHPRA in an official capacity and also issuing cannabis licences and this is an illegal practice which SAHPRA will pursue through legal channels.

SAHPRA CEO, Dr Boitumelo Semete-Makokotlela said, “This unethical and unprofessional conduct will not be tolerated, especially when it can compromise safety. Medicinal cannabis is a highly regulated area and such practices could be detrimental. At SAHPRA we value the safety of the South African public.”

Issued by:

Dr Boitumelo Semete

CEO

Boitumelo.semete@sahpra.org.za

For further enquiries /information contact:

Media contact:

Mr Yuven Gounden

Cell: 066 1202 669

E-mail: yuveng@sahpra.org.za

About SAHPRA:

SAHPRA is tasked with regulating (monitoring, evaluating, investigating, inspecting and registering) all health products. This includes clinical trials, complementary medicines, medical devices and in-vitro diagnostics (IVDs). Furthermore, SAHPRA has the added responsibility of overseeing radiation control in South Africa. SAHPRA's mandate is outlined in the Medicines and Related Substances Act (Act No 101 of 1965 as amended) as well as the Hazardous Substances Act (Act No 15 of 1973).

SAHPRA has three pillars to ensure that medicines, medical devices and IVDs meet the requisite standards to protect the health and well-being of all who reside in South Africa:

- Safety
- Efficacy
- Quality

It is these three pillars that define the ethos of SAHPRA.